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Background: Grade-III invasive ductal carcinomas of no special type (IDCs-NST) constitute a
heterogeneous group of tumours with different clinical behaviour and response to chemotherapy. As
many as 25% of all grade-III IDCs-NST are known to harbour a basal-like phenotype, as defined by gene
expression profiling or immunohistochemistry for basal cytokeratins. Patients with basal-like breast
carcinomas (BLBC) are reported to have a shorter disease-free and overall survival.
Material and methods: A retrospective analysis of 49 patients with BLBC (as defined by basal cytokeratin
expression) and 49 controls matched for age, nodal status and grade was carried out. Histological
features, immunohistochemical findings for oestrogen receptor (ER), progesterone receptor (PgR) and
HER2, and clinical outcome and survival after adjuvant chemotherapy were compared between the two
groups.
Results: It was more likely for patients with BLBCs to be found negative for ER (p,0.0001), PgR
(p,0.0001) and HER2 (p,0.01) than controls. Patients with BLBCs were found to have a significantly
higher recurrence rate (p,0.05) and were associated with significantly shorter disease-free and overall
survival (both p,0.05). In the group of patients who received anthracycline-based adjuvant chemotherapy
(BLBC group, n = 47; controls, n = 49), both disease-free and overall survival were found to be significantly
shorter in the BLBC group (p,0.05).
Conclusions: BLBCs are a distinct clinical and pathological entity, characterised by high nuclear grade,
lack of hormone receptors and HER2 expression and a more aggressive clinical course. Standard adjuvant
chemotherapy seems to be less effective in these tumours and new therapeutic approaches are indicated.
B
reast cancer is a heterogeneous disease, encompassing
many morphological and molecular genetic entities.
Invasive ductal carcinomas of no special type (IDCs-
NST) are the most prevalent histological type, accounting for
as many as 85% of all malignant breast neoplasms. Although
several markers have been used to identify specific prognostic
groups and predict response to treatment, histological grade
still remains one of the best predictors of tumour behaviour
in IDCs.1
Poorly differentiated (grade-III) IDCs are strongly asso-
ciated with shorter recurrence-free and overall survival than
grade-I and grade-II tumours.1–3 Heterogeneity is found even
within the group of poorly differentiated IDCs, and a
proportion shows a more aggressive pattern of disease.4
Molecular markers have provided additional prognostic and
predictive data for poorly differentiated IDCs. In particular,
immunohistochemical staining for hormone receptors (oes-
trogen receptor (ER) and progesterone receptor (PgR),
oncogenes (HER2), tumour suppressor genes (p53) and the
proliferative marker MIB-1) has proved to be an important
tool for defining groups of patients with more aggressive
tumours.1 3 5–7
Recently, gene expression microarray analysis redefined
breast cancer taxonomy and identified five groups associated
with distinct overall survival patterns.8–12 One of the
subgroups identified had some characteristics of basal or
myoepithelial cells in the normal breast and was associated
with a more aggressive clinical behaviour.8–12 The expression
of basal or myoepithelial markers has been observed in 2–
18% of all IDCs and in as many as 25% of grade-III
carcinomas.13 14 Most of these are high-grade tumours, have
large central acellular or necrotic zones and a high prolifera-
tion index, and are negative for hormone receptors (ER and
PgR) and HER2.4 14–22 It has been reported that this group is
associated with a higher risk for brain and lung metastases19
and for cancer-related death, independent of nodal status
and tumour size.13
Although several definitions of basal-like carcinomas have
been proposed,4 8–11 13–17 21–24 there is no internationally
accepted consensus on this. The expression of cytokeratins
(Cks) of high molecular weight, including Ck5, Ck14 and
Ck17, can be used to identify these lesions reliably on
tissue sections fixed in formalin and embedded in paraffin
wax.4 13–15 17 25 By contrast, Nielsen et al8 have developed an
immunohistochemical panel for identifying basal-like carci-
nomas on the basis of a comparison between the transcrip-
tomic and immunohistochemical profiles. According to this
definition,8 basal-like carcinomas are negative for ER and
HER2 and positive for basal cytokeratins, epidermal growth
factor receptor (HER1 or EGFR) or c-KIT. On the other hand,
others have proposed that a proportion of basal-like breast
carcinomas (BLBCs) may be positive for ER.17 21 Furthermore,
overexpression and amplification of HER2 has also been
accepted as part of the definition of basal-like carcinomas.22 23
Anecdotal experience of treating patients with a basal-like
phenotype is that they have a shorter disease-free survival
than patients with other grade-III tumours after adjuvant
chemotherapy, but only limited data are available on the
response of these tumours to different neoadjuvant ther-
apeutic regimens.26 27 We present a retrospective analysis of
the natural history, outcome and survival after chemotherapy
of patients with BLBCs diagnosed and managed at the Royal
Marsden Hospital, London, UK.
Abbreviations: BLBC, basal-like breast carcinoma; Ck, cytokeratin;
EGFR, epidermal growth factor receptor; ER, oestrogen receptor; IDCs-






A cohort of 282 patients with grade-III2 primary breast
carcinomas, diagnosed and treated at the Royal Marsden
Hospital between 1993 and 2000, were screened for the
expression of Ck5/Ck6, Ck14 and Ck17. In all, 49 (17.4%)
cases were positive for at least one of these markers and were
therefore considered to be of the basal-like subtype. The
control group consisted of 49 patients matched with the
group with basal-like tumours, according to the following
parameters: age (SD 10 years), nodal status (negative, 1–4
nodes; positive, .5 nodes) and grade (grade III). When more
than one matching control was available, that with the date
of diagnosis closest to that of the basal-like tumour was
selected. All participants in both groups were diagnosed and
treated at the Royal Marsden Hospital.
Clinical data were obtained retrospectively by using the
electronic patient record system, medical notes and the
database at the RMH. The clinical parameters documented
included disease relapse, response to treatment, disease
progression and disease-related death.
Histological and immunohistochemical analysis
All cases were independently reviewed by two of the authors
(JSRF and SRL) and representative blocks were chosen.
Tumours were graded according to a modified Bloom–
Richardson–Scarff grading system.2 Sections of 2 mm thick-
ness were cut and mounted on polylysine-coated slides.
Immunohistochemical analysis was carried out as described
previously,4 28 with antibodies against ER (clone ID5,
Dakocytomation (Glostrup, Denmark), 1:40, antigen retrie-
val: 2 min pressure cooker), PgR (clone PgR636,
Dakocytomation, 1:150, antigen retrieval: 2 min pressure
cooker), HER2 (polyclonal, Dakocytomation, 1:1200, 40 min,
antigen retrieval: water bath), Ck5/Ck6 (clone D5/16B4,
Chemicon (Temecula, CA, USA), 1:600, antigen retrieval:
18 min microwave oven, citrate buffer, pH 6), Ck14 (clone
LL002, Vector, 1:40, antigen retrieval: 18 min microwave
oven, citrate buffer, pH 6) and Ck17 (clone E3,
Dakocytomation, 1:100, antigen retrieval: 2 min pressure
cooker). Positive and negative controls were included in each
slide run and showed appropriate results.
Tumours were considered to be positive for ER and PgR
when nuclear reactivity was observed in .10% of neoplastic
cells at any intensity.29 For Ck5, Ck14 and Ck17, any
cytoplasmic expression in definite neoplastic cells or tissue
was considered to be positive.17 Evaluation of HER2 activity
was carried out according to the system used for scoring
HercepTest30 (1+, faint or barely perceptible incomplete
membrane staining in .10% of the tumour cells; 2+, weak
to moderate complete membrane staining in .10% of the
tumour cells; 3+, strong and complete membrane staining in
10% of cells). Scores of 0 and 1+ were considered to be a
negative HER2 result. Tumours scored as 3+ were considered
to be positive for HER2 overexpression. Tumours scored as 2+
were further analysed for HER2 amplification by means of
chromogenic in situ hybridisation, as described pre-
viously.25 28
For the purpose of this study, we used the definition of
basal-like carcinoma proposed by Jones et al,4 14 van de Rijn et
al,13 Laakso et al21 and Fulford et al,17 in which these tumours
are characterised by the expression of basal markers (Ck5 or
Ck14 or Ck17), regardless of the expression of hormone
receptors or HER2 (fig 1). The pathological features noted
included tumour size, nodal status, presence of vascular
invasion and the immunohistochemical profile for ER, PgR,
HER2, Ck5/Ck6, Ck14 and Ck17.
Statistical analysis
Tumour characteristics were compared between groups with
basal-like and non-basal-like (control) carcinomas by means
of the Fisher exact test or Mann–Whitney U test. Survival
Figure 1 Photomicrograph of a basal-like breast carcinoma showing a high-grade invasive ductal carcinoma not otherwise specified, composed of
sheets and cords of polygonal, epithelioid atypical cells, with marked pleomorphism, moderate eosinophilic cytoplasm and conspicuous mitotic activity.
(A) Staining with haematoxylin–eosin; (B) cytokeratin (Ck) 14; (C) Ck5/Ck6; and (D) Ck17.
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and disease-free survival were measured from the date of
diagnosis until death or relapse in any site, or date of last
follow-up. Survival curves were drawn by the Kaplan–Meier
method and differences assessed by the log-rank test. All
tests were two tailed, with a confidence interval of 95%.
Multivariate analysis was carried out with Cox’s multiple
hazards model and p = 0.1 in the univariate survival analysis
was adopted as the limit for inclusion in the multivariate
model. Cases with missing values were excluded. Data were
statistically analysed with SPSS and Statview.
RESULTS
Table 1 summarises the histopathological and immunohisto-
chemical features of the basal-like and control carcinomas.
Briefly, basal-like carcinomas were more frequently ER
negative (p,0.0001), PgR negative (p,0.0001) and HER2
negative (p,0.01) than controls. Table 2 gives the tumour
characteristics of the group with basal-like carcinoma and of
the matched controls. The median follow-up time for the
group with basal-like carcinoma was 68.1 (range 9.0–
134.2) months, which was similar to that for the controls
(median 72.3, range 7.5–191.1 months).
Basal-like carcinomas showed a higher recurrence rate
(42.8%) than controls (20.4%; p,0.05). These tumours also
showed a significantly shorter disease-free survival (fig 2A;
p,0.05) and overall survival (fig 2B; p,0.05). At 5 years, the
actuarial disease-free survival was significantly different in
patients with basal-like and control carcinomas (61.1% v
89.8%, respectively; p,0.05). The actuarial overall survival at
5 years was also significantly lower in patients with basal-
like carcinomas than in the control group (69.3% v 91.8%,
respectively; p,0.05).
The number of patients receiving anthracycline-based
adjuvant chemotherapy—namely 5-fluorouracil and cyclo-
phosphamide and either epirubicin or adriamycin—was
similar in both groups (basal-like, n = 47; controls, n = 49).
Taking into account only those patients who received the
same type of adjuvant chemotherapy, the disease-free
survival and overall survival were also significantly shorter
in patients in the BLBC group (figs 3A,B; p,0.05). In
multivariate analysis including ER, PgR, lymph–vascular
invasion, endocrine therapy and basal-like status, none of
the variables reached statistical significance for disease-free
and overall survival.
Recurrent disease
Twenty patients in the BLBC group developed relapsed
disease. Table 3 outlines the sites of disease relapse. Fifteen
patients were treated with chemotherapy either alone or in
combination with radiotherapy, endocrine therapy or surgery
for metastatic disease. The response to treatment was
documented in 4 (27%) of these patients; response duration
ranged from 1 to 6 months (table 4). Table 5 summarises the




Tumour size (mm) Median (range) 20 (5–68) 20 (4–60) p = 0.5 (Mann–
Whitney)
Vascular invasion Negative 23 17 p.0.1
Positive 26 32
Tumour markers
Ck14 Positive 32 0 ND
Negative 17 49
Ck5/Ck6 Positive 32 0 ND
Negative 17 49
Ck17 Positive 31 0 ND
Negative 18 49
Ck14 and Ck5/Ck6 Positive 25 0 ND
Negative 24 49
Ck14 and Ck17 Positive 31 0 ND
Negative 18 49
Ck5/Ck6 and Ck17 Positive 17 0 ND
Negative 32 49
All Ck Positive 15 0 ND
Negative 34 49
ER status Negative 40 11 p,0.0001
Positive 9 38
PgR status Negative 39 14 p,0.0001
Positive 10 35
HER2 status* Negative 45 34 p,0.01
Positive 4 15
Ck, cytokeratin; ER, oestrogen receptor; ND, not done (definition criteria); PgR: progesterone receptor.
*One basal-like carcinoma and one control were scored as HER2 2+ by immunohistochemical analysis; however,
both failed to show HER2 amplification by chromogenic in situ hybridisation (data not shown). Therefore, these
cases were considered to be negative for HER2 amplification or overexpression.
Table 2 Summary of the clinical features of basal-like

















.5 nodes 10 10
Primary treatment








Endocrine None 19 6 p,0.005
Tamoxifen 30 43
Radiotherapy None 9 5 p = 0.4
Yes 40 44
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clinical course of the patients who did not respond to
chemotherapy. Two patients received radiotherapy alone for
metastatic disease to the brain. Both patients died within
4 months of the diagnosis of metastatic disease. In addition,
three patients received treatment for local relapse.
DISCUSSION
BLBCs have attracted considerable attention over the past
few years. The genes and molecular markers expressed in
these tumours suggest that they are distinct biological
entities, with an aggressive clinical behaviour and a
characteristic pattern of metastatic spread. Our results
corroborate those of others, in that basal-like carcinomas
were more frequently negative for ER, PgR and HER2 than
non-basal-like carcinomas.4 13 15 16 21 Furthermore, patients
with basal-like tumours showed shorter disease-free and
overall survival when compared with patients matched for
age, nodal status and grade of non-BLBCs.4 8 13 15 16 van de
Rijn et al13 also showed that basal-like carcinomas (defined as
those tumours expressing Ck17 or Ck5) were associated with
a markedly worse prognosis than tumours negative for basal
keratins. In the group of patients that was node negative, the
expression of basal markers was a prognostic factor that was
independent of tumour size, grade, HER2 and ER status.13
By using a different definition for basal-like carcinomas,
comprising negativity for ER and HER2 and expression of at
least one basal marker, Nielsen et al8 showed that the disease-
specific survival of patients with basal-like carcinomas is
shorter than that of patients with ER-positive tumours.
Interestingly, in this study,8 patients with HER2-positive
tumours had a shorter overall survival than those with basal-
like tumours. This finding is in contrast with the results
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A Disease Free survival B Overall survival
Figure 2 Kaplan–Meier curves for (A) disease-free and (B) overall survival for all patients.
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A Disease Free survival B Overall survival
Figure 3 Kaplan–Meier curves for (A) disease-free and (B) overall survival for patients treated with adjuvant chemotherapy.
Table 3 Site distribution of disease relapse, including
locoregional recurrence and distant metastases
Site of relapse





Local recurrence 8 2 8 2
Soft tissue and skin 0 0 4 0
Lymph nodes (non-regional) 6 1 9 1
Bone 4 1 6 1
Liver 3 1 5 1
Lung and pleura 6 3 11 3
Brain 3 0 5 0
Total number of events 30 8 48 8
*All concurrent metastatic events were considered to be independent
events.
Local recurrence was defined as recurrence in the ipsilateral breast, skin
and regional nodes.
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published by Sørlie et al,9 in which patients with basal-like
carcinomas showed the shortest overall survival. In our
previous report on immunohistochemical and comparative
genomic hybridisation analysis of grade-III IDCs-NST with
extensive follow-up, we showed that basal-like tumours may
be heterogeneous with ‘‘good’’ and ‘‘bad’’ prognosis groups,4
and this may partly account for some of the differences in
outcome seen in different groups.
Basal markers are not routinely used in the standard
histological diagnosis of breast cancer. As existing prognostic
markers do not identify this group, patients with basal-like
and non-basal-like tumours are currently treated similarly. A
potential explanation for the poorer clinical outcome of
patients with basal-like tumours is that this subset can be
less responsive to chemotherapy. In our study we have shown
data suggesting that adjuvant anthracycline-based che-
motherapy is less effective in patients with basal-like
carcinomas than in controls matched for age, nodal status
and grade. Furthermore, we found that only a few of these
tumours responded to chemotherapy after systemic relapse.







relapse of disease Response
Time from
response to






1 19 Bone, LN MVP 6 cycles DXT
(bone)
PR (post cycle 3
and 6, CT)
6 Breast LN Doxorubicin (4 cycles) 17
2 20 Bone, liver Doxorubicin 6 cycles PR (post cycle 3
and 6, CT)





PR post 2 cycles
PD post 4 cycles
(clinical)
1 Chest wall, LN Letrozole 2 months PD





4 12 LN neck,
axilla
Surgery DXT PD on
treatment docetaxel
4 cycles
PR (post 2 cycles,
US)
2 LN FTI 3 months PD chest
wall vinorelbine+5FU
(2 cycles) PD chest
wall, LN MVP
(7 cycles) PD lung
14
5-FU, 5-fluorouracil; CT, computed tomography; DXT, radiotherapy; FTI, farnesyl transferase inhibitor; LN, lymph nodes; MVP, mitomycin, vinblastine, cisplatin;
PD, progressive disease; PR, partial response; US, ultrasound.
Table 5 Summaries of clinical histories of patients with basal-like tumours not responding to chemotherapy
Case number
Disease-free survival
(months) Site of relapse Treatment after relapse of disease




1 8 LN MVP (2 cycles) PD lung, breast, LN 5 13
Ifosfamide (2 cycles) PD
Paclitaxel (1 cycle) PD
5-FU (1 cycle) PD
Docetaxel (1 cycle) PD
2 27 Liver, bone, LN Vinorelbine (2 cycles) 2 29
3 60 Bone Docetaxel (6 cycles) PD liver, lung, bone megestrol 7 67
4 37 Brain, lung DXT brain docetaxel (4 cycles) 8 45
5 48 Bone DXT bone 15 63
Letrozole 2 months PD
Paclitaxel (6 cycles) PD
Exemestane 13 months PD brain
DXT brain
Capecitabine
6 19 Bilateral breast, axilla Docetaxel (4 cycles) 7 26
MVP (1 cycle)
7 5 Lung Docetaxel (2 cycles) 5 10
8 16 Skin, axilla FTI PD pericardial effusion 11 27
Vinorelbine (2 cycles) PD chest wall
Docetaxel (4 cycles) PD lung
MVP (1 cycle)
9 28 Liver, lung Vinorelbine/epirubicin (1 cycle) 0.8 28.8
10 7 Ipsilateral LN Surgery 37 44
Adjuvant FEC (6 cycles)
PD skin
Miftefosine 7 months PD
Herceptin 10 months PD lung
Taxoprexin (5 cycles) PD lung
Vinorelbine (2 cycles) PD bone
11 7 Ipsilateral LN Surgery 3 10
Adjuvant CMF (2 cycles) PD lung
Bleomycin (1 cycle) PD
Doxorubicin (1 cycle) PD
Megestrol (1 week)
5-FU, 5-fluorouracil; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; FTI, farnesyl transferase inhibitor; LN, lymph nodes; MVP, mitomycin, vinblastine,
cisplatin; PD, progressive disease, PR, partial response.
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Further data on the response of metastatic disease to
chemotherapy are now needed, but it may be that patients
with basal-like carcinomas are less sensitive to standard
adjuvant chemotherapy than those with other types of breast
cancer, and that distinct, novel therapeutic approaches are
required.
By contrast, data from other studies on the response to a
neoadjuvant chemotherapy regimen in patients in the BLBC
group suggested that the clinical response to adriamycin and
cyclophosphamide was markedly higher among patients with
basal-like tumours than among those with non-basal-like
tumours. Pathological complete response to neoadjuvant
chemotherapy was higher in patients with basal-like tumours
than in those with non-basal-like tumours.26 In another
study,27 responses to neoadjuvant chemotherapy (paclitaxel,
doxorubicin, 5-fluorouracil and cyclophosphamide) for basal-
like, HER2, luminal and normal BLBC showed that BLBCs
and HER2 tumours were significantly more likely to have
pathological complete response to chemotherapy (p,0.01)
than the other groups.27 The differences between our findings
and those from neoadjuvant studies26 may be due to
differences in the cohorts analysed and in the definition of
basal-like tumours.4 8–11 13–17 21–23 Whereas Rouzier et al and
Carey et al analysed cohorts with a mixture of breast
carcinomas of grades I, II and III, we included only grade-
III tumours in our study. Furthermore, Carey et al26 defined
basal-like tumours as those lacking expression of ER, PgR
and HER2, whereas Rouzier et al27 used a transcriptomic
definition for these tumours. Neither of these studies used
immunohistochemical analysis for basal cytokeratins in the
definition.
It has been shown that basal-like carcinomas consistently
overexpress HER1 or EGFR8 31 32 and there may be a role for
EGFR inhibitors in the treatment of this tumour subset.
Tumours arising in carriers of the BRCA1 germline mutation
often show transcriptomic and immunohistochemical pro-
files similar to those of basal-like carcinomas.32–34 BRCA1-
associated tumours harbour defects in specific DNA double-
strand break–repair pathways and may show selective
sensitivity to DNA cross-linking chemotherapeutic agents
such as cisplatin and carboplatin.34 Basal tumours showing
hallmarks of ‘‘BRCAness’’34 may show similar sensitivity and
these drugs may be more effective in the treatment of this
group.
In conclusion, basal-like carcinomas constitute a discrete
clinical and pathological entity, characterised by high nuclear
grade and a propensity for lack of ER, PgR and HER2
expression. These tumours have a more aggressive clinical
course, as shown by shorter disease-free and overall survival
after standard adjuvant anthracycline-based chemotherapy,
than otherwise matched non-basal-like tumours. New treat-
ment options should be investigated for patients with this
subtype of breast cancer.
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